» Articles » PMID: 11843838

Plasma of Patients with Upshaw-Schulman Syndrome, a Congenital Deficiency of Von Willebrand Factor-cleaving Protease Activity, Enhances the Aggregation of Normal Platelets Under High Shear Stress

Overview
Journal Br J Haematol
Specialty Hematology
Date 2002 Feb 15
PMID 11843838
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Upshaw-Schulman syndrome (USS) is an autosomal recessive disorder characterized by repeated episodes of chronic thrombocytopenia and microangiopathic haemolytic anaemia (MAHA) that responds dramatically to infusions of fresh frozen plasma (FFP). Recent studies have provided consistent evidence that USS is a congenital deficiency of plasma von Willebrand factor-cleaving protease (VWF-CPase) activity and, therefore, unusually large VWF multimers (UL-VWFMs) are present in the plasma. However, the molecular mechanism of the clinical symptoms of USS is not well understood. We studied the relationship between UL-VWFMs and thrombocytopenia in two USS patients by analysing platelet aggregation using a mixture of the patient's plasma and normal washed platelets under high shear stress. Our results clearly showed a remarkably enhanced high shear stress-induced platelet aggregation (H-SIPA) by the patient's plasma. At 24 h after FFP infusion (approximately equal to 10 ml/kg body weight), the enhanced H-SIPA became almost completely normalized but, 2 d later, it began to return to the preinfusion level. These results were in accordance with the change in VWFM patterns. The specific effects of enhanced H-SIPA on VWF, platelet glycoprotein Ib and endogenous ADP released from platelets upon stimulation were confirmed using reagents that specifically inhibit their respective functions. Our present results clearly indicate that thrombocytopenia in USS patients is caused by a combination of the presence of UL-VWFMs, platelets and high shear stress generated in the microcirculation.

Citing Articles

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis.

Uemura M, Fujimura Y, Ko S, Matsumoto M, Nakajima Y, Fukui H Int J Hepatol. 2011; 2011():759047.

PMID: 21994870 PMC: 3170842. DOI: 10.4061/2011/759047.


A new name in thrombosis, ADAMTS13.

Sadler J Proc Natl Acad Sci U S A. 2002; 99(18):11552-4.

PMID: 12195022 PMC: 129303. DOI: 10.1073/pnas.192448999.


Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.

Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M Proc Natl Acad Sci U S A. 2002; 99(18):11902-7.

PMID: 12181489 PMC: 129366. DOI: 10.1073/pnas.172277399.


Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K Int J Hematol. 2002; 75(1):25-34.

PMID: 11843286 DOI: 10.1007/BF02981975.